Shield Therapeutics plc (STX) Ordinary Shares 1.5p

Sell:4.40pBuy:4.80p0.10p (2.17%)

Prices delayed by at least 15 minutes
Sell:4.40p
Buy:4.80p
Change:0.10p (2.17%)
Deal now
Prices delayed by at least 15 minutes
Sell:4.40p
Buy:4.80p
Change:0.10p (2.17%)
Prices delayed by at least 15 minutes
Deal now

Company Information

About this company

Shield Therapeutics plc is a United Kingdom-based commercial-stage pharmaceutical company. The Company delivers differentiated specialty pharmaceuticals that address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company’s lead product, Accrufer/Feraccru, is broadly indicated for use in adults across multiple therapeutic categories. Ferric maltol is approved in the United States, European Union, the United Kingdom, Canada, Australia and Switzerland for the treatment of iron deficiency with or without anemia in adults. It also has an exclusive licence agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialization of ACCRUFeR/FeRACCRU in China, Hong Kong, Macau and Taiwan, with Korea Pharma Co., Ltd. for the Republic of Korea. The Company's subsidiaries include Phosphate Therapeutics Limited, Shield TX (Switzerland) AG, Shield Therapeutics Inc, and Shield TX (UK) Limited.

Key people

Anders Lundstrom
Chief Executive Officer, Executive Director
Santosh Shanbhag
Chief Financial Officer
Lucy Huntington-Bailey
Chief Compliance Officer, General Counsel, Company Secretary
David Childs
Vice President - Manufacturing and Strategic Alliances
Jackie Mitchell
Vice President - Quality, Clinical and Regulatory Affairs
Andy Hurley
Chief Commercial Officer
Hans Peter Hasler
Non-Executive Independent Chairman of the Board
Peter Llewellyn-Davies
Non-Executive Independent Vice Chairman of the Board
Christian Schweiger
Non-Executive Director
Rudolf Widmann
Non-Executive Director
Fabiana Lacerca-Allen
Non-Executive Independent Director
Click to see more

Key facts

  • EPIC
    STX
  • Location
    United Kingdom
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    GB00BYV81293
  • Market cap
    £46.88m
  • Employees
    77
  • Shares in issue
    1.04bn
  • Exchange
    London Stock Exchange (LON)
  • Index
  • Website
    Visit website

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.